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Abstract Certain ethnic groups seem to have less access to
cancer genetic counseling. Our study was to investigate the
participation in cancer genetic counseling among migrant
breast cancer patients of Turkish and Moroccan origin.
Hospital medical records of Turkish and Moroccan and of a
comparative group of non-Turkish/Moroccan newly diag-
nosed breast cancer patients were studied. All women were
diagnosed between 2007 and 2012. Eligibility for genetic
counseling was assessed with a checklist. A total of 156
Turkish/Moroccan patients were identified, and 321 patients
were assigned to the comparative group. About one third
(35 %) of the Turkish/Moroccan patients fulfilled criteria for
breast cancer genetic counseling, compared to 21 % of the
comparative group (P = 0.001); this was largely due to a
relatively young age at diagnosis in the migrant group (26 %
\40 years vs 5 % in the comparative group, P = 0.0001).
Uptake of genetic counseling among eligible patients was
47 % in the migrant group and 56 % in the comparative
group; differences in uptake were seen among the patients
diagnosed before 40 years of age (48 % in themigrant group
vs 81 % in the comparative group; P = 0.021). When
adjusted for age at diagnosis, ethnicity was associated with
discussing referral to genetic counseling and its actual
uptake. The Turkish/Moroccan ethnicity appears to be
associated with a lower uptake of genetic counseling, mainly
caused by the lower uptake in the young age-group. The
major barrier to participation in genetic counseling seems to
lie within the referral process.
Keywords Cancer  Oncology  Genetic testing  Breast 
Moroccan  Turkish
Introduction
In general, a BRCA mutation is detected in about 10 % of
the tested breast cancer patients [1]. Because younger
women diagnosed with breast cancer and those with a
Preliminary results are presented (oral presentation) at the European
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Meeting on Psychosocial Aspects of Genetics 2014, Milan, Italy, May
31-June 3, 2014.
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family history of breast and/or ovarian cancer are at higher
risk of carrying a BRCA1/2 gene mutation, diagnostic
DNA testing is offered to this subset of breast cancer
patients [2].
Once these patients are referred by their physicians to
family cancer clinics they can opt for genetic counseling
and testing (GCT). During GCT genetic counselors give
information about the risk to develop (a second) cancer for
the patient and her relatives and about options for cancer
prevention and early detection [3].
Hall and coworkers [4] showed that the prevalence of
BRCA1/2 mutations is high and nearly identical across
different ethnicities, not only in Caucasian women. How-
ever, testing volumes were disproportionately low among
women from non-European ancestry [4]. Others also
observed a low uptake of GCT among ethnic minorities,
i.e. Afro-Americans and Hispanics in the US [5–8].
Known barriers towards the use of GCT were socioe-
conomic barriers (e.g., time, access, costs, geographic,
awareness, language and cultural) and psychosocial barri-
ers (e.g., inaccurate cancer risk perception, medical mis-
trust and perceived disadvantages to genetic services) [6, 9,
10].
Also in the Netherlands, patients from non-Western
descent seem to be underrepresented in cancer GCT [11].
At present, in the Netherlands nearly two million (12 %) of
the population have a non-Western background [12]. About
40 % of the inhabitants from non-Western descent are from
Turkish (20 %) and Moroccan (19 %) origin [12], which
makes them the largest migrant groups in the Netherlands.
The first generation of these mostly low educated migrant
groups is known to have major language difficulties [13],
which may hamper their access to health care. Although
breast cancer among Turkish and Moroccan migrant
women is less prevalent than among native women [14,
15], higher relative excess mortality from breast cancer in
these migrant women might point toward inadequate
access to health care and treatment in this group [14].
In Turkey and Morocco, the countries of origin, studies
addressing GCT among breast cancer patients are yet
upcoming and mainly focus on the prevalence of BRCA
mutations [16–20]. However, these studies do not reflect on
referral rates and participation in GCT, which is as yet
unknown. In many Arabic cultures and countries of the
Greater Middle East, a cancer diagnosis is still accompa-
nied with social stigma and misperceptions regarding the
incurability of the disease [21], which could hinder the
participation in breast cancer genetic counseling.
The aim of the present study is to investigate the par-
ticipation of Turkish and Moroccan patients in breast
cancer GCT. More specifically, our research questions
include: (1) What proportion of Turkish and Moroccan
breast cancer patients fulfils criteria for referral for GCT
and what is the actual uptake?; (2) Does eligibility and
uptake differ from non-Turkish/Moroccan patients?; (3) Is




The study population included a Moroccan and Turkish
patient group and a non-Turkish/Moroccan patient group.
These patients were diagnosed with breast cancer between
January 2007 and December 2012 in six hospitals in the
Utrecht region and in Amsterdam, the Netherlands.
Procedure
Medical records of female breast cancer patients were
studied between April 2013 and April 2014. Patients from
Turkish and Moroccan descent were identified by a name-
based approach. This approach has been used in different
scientific studies among Turks and Moroccans in the
Netherlands and Germany [15, 22–25]. If information
about the country of birth was available in the medical
records, Moroccan/Turkish ethnicity was checked and
registered. Because our pilot study among Turkish and
Moroccan breast cancer patients showed a higher eligibility
to genetic counseling compared to the average Dutch breast
cancer patient population, a twice as large comparative
group of the remaining non-Turkish and non-Moroccan
breast cancer patients was randomly selected by SPSS per
hospital, to get an about equally large comparison group
(see ‘‘Appendix’’). The medical records were studied by JB
and MV, the first 20 checklists were filled in by both
researchers together. A random sample of 10 % of the
checklists were filled in by both researchers, which showed
an interrater reliability of 0.94 (Cohen’s kappa) on the
variables shown in Table 1.
Variables
Data extracted from the medical records with a checklist
included variables to assess the eligibility for GCT, such as
age at diagnosis and characteristics of the patient and the
family history, if present (see Table 1). Because the
patients were diagnosed in the years 2007–2012, the eli-
gibility criteria were based on the national guidelines of
that time [26], except for early age at diagnosis (e.g. before
40 years of age was common practice). Other variables to
be noted were: ethnicity, year of birth, type of surgery,
TNM stage, and whether language problems were reported
and an interpreter was present during consultations.
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Finally, we assessed ‘discussing GCT referral’ which rep-
resents whether or not referral to GCT was discussed with
the patient and reported in the medical file, and the actual
‘uptake’ of GCT. In case a discussion with the patient
about GCT was not reported in the medical record, but
GCT was performed (uptake was positive), patients were
automatically coded as ‘having discussed GCT referral’.
Information in the medical records about the family
history was coded into three categories; (1) a complete
family history: information about the occurrence or
absence of breast and ovarian cancer in the family was
present; (2) a ‘partial’ family history: only information
about family history of breast cancer, and (3) ‘no infor-
mation’: no information about the family history of breast
and ovarian cancer.
Analysis
Differences between groups were analysed with Chi square
and Student’s t tests. Furthermore, to answer the third
research question (to identify determinants for the uptake
of genetic counseling and to explore whether ethnicity is
associated with GCT uptake), a logistic regression analysis
was performed within those eligible for genetic counseling
in the total sample. Independent variables included eth-
nicity (Turkish/Moroccan versus non-Turkish/Moroccan);
furthermore, potential determinants to be related to the
outcome variable (i.e. age at diagnosis, TNM-stage, lan-
guage difficulties, criteria for discussing GCT referral to
genetic counseling (e.g. family history, year of diagnosis,
see Table 2) were univariately tested and if correlated with
the outcome variables (P\ 0.05), they were included in
the logistic regression analysis.
Results
Socio-demographic and clinical variables
For the period 2007–2012 we identified 156 female
migrant breast cancer patients (55 with a Turkish and 101
with a Moroccan background) using the name-based
approach and 321 female patients were randomly assigned
to the comparative group (see flowchart in ‘‘Appendix’’).
Patient characteristics are shown in Table 2. Statistically
significant differences between groups were found for the
mean age at diagnosis, and the levels of the TNM-stages.
Moroccan women had a higher proportion of TNM-stage
IV. In the total Turkish/Moroccan group there were less
patients with a more favourable disease stage compared to
the comparative group.
In 44 % of Turkish/Moroccan patient records, the
records indicated that the patient had poor or no mastery of
the Dutch language. In 34 % of all Turkish/Moroccan
patients one or more consultations had been translated by
an interpreter, mostly family-related.
Criteria for referral to GCT
A higher proportion of the total group of Turkish/Moroccan
breast cancer patients fulfilled criteria for referral to genetic
counseling (35 %) as compared to the non-Turkish/Moroc-
can comparative group (21 %; P = 0.001). This difference
was caused by the large portion of Turkish/Moroccan
patients who were younger than 40 years of age when
diagnosed (26 % in the Turkish/Moroccan group compared
to 5 % in the comparative group; P = 0.0001; see Table 3).
Family history
The majority of patients had some data on their family
history in their medical file. In the medical records of 42 %
in the Turkish/Moroccan group and 39 % in the compar-
ative group a ‘complete’ family history was found. In about
half of the patients in the Turkish/Moroccan group (49 %)
and in the comparative group (47 %) the information in the
medical file included only information about the family
history of breast cancer and not about ovarian cancer (a
‘partial’ family history). No differences between the groups
were found with regard to the information on family his-
tory in the medical records (P = 0.23).
Uptake of breast cancer genetic counseling
and testing
Discussing the possibilities of GCT with the patient and
proposing referral is a necessary step to get access to
Table 1 Checklist criteria for eligibility to be referred to breast
cancer genetic counselling
One or more of the following
Breast cancer diagnosis\40 years of age
Breast cancer diagnosis\50 years of age and
Bilateral breast cancer (synchronic or metachronic)
First degree relative with breast cancer
Breast cancer diagnosis at any age and
Known BRCA1/2 mutation in the family*
Personal history of contralateral breast cancer\50 years
Personal history of ipsilateral breast cancer\50 years*
Personal history of ovarian cancer*
Relative with ovarian cancer in the same part of the family
Male relative with breast cancer in the same part of the family*
Two or more first/second degree relatives with breast cancer in
the same part of the family
* Not included in the overall Cohen’s Kappa, because the variable is a
constant (and 100 % agreement)
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cancer genetic counseling and DNA testing. Table 4 shows
the proportion of eligible patients who had discussed GCT
with their physician (‘discussing GCT referral’) and the
proportion of eligible patients who received GCT
(‘uptake’).
When looking at patients eligible for GCT, we found no
statistically significant differences between both groups
with regard to discussing GCT referral and uptake of GCT.
When focusing on the younger patients (\40 years at
diagnosis) only, a trend was observed for discussing GCT
referral: with 55 % of patients in the Turkish/Moroccan
group GCT had been discussed, compared to 81 % in the
comparative group (P = 0.067). Also the actual uptake
differed between the groups eligible for genetic counseling
due to their young age at diagnosis (\40 years) (48 % in
the Turkish/Moroccan group versus 81 % in the compar-
ative group (P = 0.02).
To study whether ethnicity was associated with ‘dis-
cussing GCT referral’ and ‘uptake of GCT’, variables that
were significantly correlated with discussing GCT referral
and uptake of GCT were included in a logistic regression
analysis, with ethnicity as one of the independent variables.
When controlled for age at diagnosis, Turkish/Moroccan
ethnicity was negatively associated with ‘discussing GCT’
referral and ‘uptake of GCT’ (Table 5).
Discussion
Overall, the participation in GCT among eligible breast
cancer patients was about the same amongst the migrant
group and a comparative group of randomly selected non-
Turkish/Moroccan patients. However, we found lower
GCT participation rates among young Turkish/Moroccan
migrant breast cancer patients (\40 years at diagnosis).
When controlled for age at diagnosis, ethnicity showed to
be a predictor of ‘discussing GCT referral’ as well as
‘uptake of breast cancer GCT’. Our data suggest that the
major barrier to the uptake of GCT within Turkish and
Moroccan migrant groups lies within the referral process.
Once referred, our data shows most are likely to follow the
advice of their physician. Our study showed that nearly half
of the migrant breast cancer patients had major language
difficulties, however this was not a predictor of lower
uptake. Possibly, language barriers, for example when a
consultation is translated by a family member, might be
underreported in the medical files. It is as yet unknown
what may contribute to a lower participation in GCT
among young migrant breast cancer patients of Turkish/
Moroccan origin. From the perspective of the physician,
failure to identify and refer eligible women towards GCT
may be related to the lack of time to assess a complete














Socio-demographic and clinical variables
Age at diagnosis mean (SD) 51.70 (12.61) 47.81 (11.21) 0.05 49.18 (11.83) 61.73 (14.62) 0.0001
Surgery
BCT 35 (66.0) 56 (57.7) 0.32 91 (60.7) 178 (59.3) 0.79
Mastectomy 18 (34.0) 41 (42.3) 59 (39.3) 122 (40.7)
TNM-stage
0–I 41 (75.9) 55 (56.7) 0.02 96 (63.6) 225 (74.8) 0.01
II 3 (5.6) 20 (20.6) 23 (15.2) 45 (15.0)
III 7 (13.0) 9 (56.2) 16 (10.6) 19 (6.3)
IV 3 (5.6) 13 (13.4) 16 (10.6) 12 (4.0)
Poor or no mastery of Dutch
language
28 (50.9) 40 (39.6) 0.17 68 (43.6) 4 (1.2) 0.0001
Consultation translated 23 (41.8) 30 (29.7) 0.13 53 (34.0) 2 (0.6) 0.0001
By family 19 (34.5) 28 (27.7) 47 (30.1) 2 (0.6)
C1 time by professional 4 (7.3) 2 (2.0) 6 (3.8) (0)
BCT breast conserving therapy, TNM tumor, nodes, metastases, TNM staging takes into account the size of the tumour (T), whether the cancer
has spread to the lymph nodes (N), and whether there are metastases (M)
The TNM-stages are defined from group 0 through IV, and indicate the increasing extent of disease at the time of the initial diagnosis. Stage 0
includes breast cancer in situ, Stages I–III include different tumour sizes and lymph nodes without distant metastases, and Stage IV indicates the
presence of distant metastases
* Number of respondents may vary across variables according to missing data
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Total eligible 18 (32.7) 37 (36.6) 0.63 55 (35.3) 66 (20.6) 0.001
Personal cancer history
Age at diagnose
\40 years 11 (20.0) 29 (28.7) 0.23 40 (25.6) 16 (5.0) 0.0001
Contralateral or ipsilateral
BC\ 50 years
2 (3.6) 3 (3.0) – 5 (3.2) 7 (2.2) 0.503
OVCA 0 0 – 0 (0) 2 (0.6) –
Family cancer history
OVCA in family 0 1 (1) – 1 (0.6) 12 (3.7) –
BC in family 8 (14.5) 8 (7.9) 0.19 16 (10.3) 39 (12.1) 0.54
Male BC in family 1 (1.8) 2 (2.0) – 3 (1.9) 1 (0.3) –
BC breast cancer, OVCA ovarian cancer
Contralateral or ipsilateral BC\ 50 years: BC patients of all ages with a contralateral and/or ipsilateral BC diagnosed before the age of 50
OVCA in family: all BC patients who have a family member with OVCA
For a few variables, Chi square statistics could not be calculated because[ 20 % of the cells had an expected count of 0.5
BC in family: BC patients of all ages at diagnosis who have two or more first and/or second degree family members with BC (same family
branch) and/or one first degree family member with BC diagnosed before the age of 50 and/or patients who were younger than 50 years at
diagnosis who have at least one family member with BC
Male BC: 1 or more male first degree family members with BC
* Patients can fulfil one or more criteria
Table 4 ‘Discussing GCT referral’ and ‘uptake’ in genetic counseling and testing













Total eligible 55 31 (56.4) 26 (47) 66 39 (59.1) 34 (56)
Age at diagnosis\40 40 22 (55.0)* 19 (47.5) 16 13 (81.2)* 13 (81.2)
Fam history BC/OVCA 17 12 (70.6) 11 (64.7) 48 27 (56.3) 25 (52.1)
GCT Genetic counselling and testing
Fam history BC/OVCA: 2 or more first and/or second degree family members with BC (same family branch) and/or a family member with
history of ovarian cancer
Participants can fulfil one or more criteria as shown in Table 3; furthermore, the ‘Total eligible group’ also includes patients with contralateral or
ipsilateral breast cancer\50 years who did not fulfil the criteria ‘Age at diagnosis\40-group’ nor the ‘Fam history BC/OVCA’
* P = 0.067
 P = 0.021
Table 5 Adjusted odds ratios
and 95 % CIs for ‘discussing
GCT referral’ and BRCA1/2
testing among breast cancer
patients eligible for GCT
Predictors Discuss GCT referral Uptake of GCT
Adjusted OR (95 % CI) Adjusted OR (95 % CI)
Total N = 121 N = 121
Age at diagnosis (continuous variable) 0.92 (0.88–0.96) 0.92 (0.88–0.96)
Ethnicity
Non-Turkish/Moroccan (ref)
Turkish/Moroccan 0.38 (0.15–0.93) 0.28 (0.11–0.71)
Nagelkerke R square 0.21 0.22
P value model 0.0001 0.0001
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familial cancer history [27]; yet, our study showed no
differences in assessing family history between the ethnic
groups. We know that the Turkish and Moroccan migrant
groups in the Netherlands are generally low educated [13].
From other studies on health inequalities in cancer care it
seems that lower educated people are more prone to less
adequate care [28]. Further study should focus on the
possible barriers in the Turkish and Moroccan groups and
should explore the perceptions of the physicians.
Ethnicity and the age at diagnosis were predictors of
‘discussing GCT referral’ and ‘uptake of GCT’ in a mul-
tivariate analysis. The latter seems to be the strongest
predictor of discussing GCT referral and uptake of GCT in
the total group eligible; the younger the patient, the more
likely they are to be referred to GCT.
As shown in our study, a large proportion of Turkish
and Moroccan breast cancer patients is eligible for GCT
due to a young age at diagnosis (26 %). This is note-
worthy, given that in the general population of invasive
and non-invasive breast cancer patients in the Netherlands,
only 4.4 % is younger than 40 years at time of diagnosis
[29]. This proportion corresponds to our results in the
comparative group. The relatively young age at diagnosis
in the migrant group is in line with studies in Turkey and
Morocco [30–33]. There could be a variety of factors
contributing to the relatively high proportion of young
migrant breast cancer patients, such as lifestyle related and
reproductive factors, which are likely to be influenced by
the acculturation process. Another possible explanation
lies in the dissimilar age-distribution of the migrant pop-
ulations in the host-country. Dutch demographics show a
relatively young Turkish and Moroccan population with
rather few older people as compared to the Dutch native
population [34]. Further studies are needed to investigate
determinants for the relatively large group of young
individuals within the total migrant breast cancer patient
population.
There are a number of limitations in this study including
its retrospective design based on medical records, the
generalizability of the results, and the relatively small
sample sizes. Although it was the best available option, our
name-based approach could have biased our results in the
sense that we could have missed patients who have an
extraordinary name. Furthermore, a name-based approach
might miss patients who adopted the name of a native
spouse. However, full names were checked, and Turkish
and Moroccan women tend to marry within the same cul-
tural background [35]. In our analyses we have taken the
Turkish and the Moroccan patients together because these
are both large migrant groups, both have language barriers,
and mostly a lower social economic status. Despite the fact
that they share a lot of similarities, one should be aware
that these are also culturally diverse groups. With regard to
the comparative group, it can not be excluded that this
group contained other (Western and non-Western) migrant
patients. It is possible that other migrant groups also have a
low referral to and uptake of genetic counselling, and the
differences between groups may therefore be under-esti-
mated. Furthermore, a possible incompleteness of the
registration in the hospital records might have resulted in
an underestimation of discussing GCT referral and uptake
rates. We had access to the hospital medical records of the
participating six hospitals. Patients could have been refer-
red to other hospitals for example for adjuvant radiother-
apy, and these records have not been checked because they
fall out of the scope of the current study. Moreover, the
degree in which information such as the family pedigree
was organised in the electronic medical records differed
between the hospitals. Although the good interrater relia-
bility suggests that this did not affect the quality of our
data, a unified form of recording family history should be
recommended to get an easier view and clearer picture of
the family pedigree.
Referral for genetic counseling may contribute to early
breast cancer detection and intervention. Besides preven-
tive measures that are available for patients who test pos-
itive for a BRCA1/2 gene mutation and have increased risk
to develop a second primary breast cancer and ovarian
cancer [36–38], GCT also provides information for the
family members of tested individuals. Also for patients
with an inconclusive test result (no pathogenic BRCA gene
mutation has been found), an increased breast cancer risk
for relatives cannot be ruled out. During the counseling
sessions, the affected—index—patients receive informa-
tion such as their family members’ breast cancer risks and
screening possibilities. Therefore, it is of importance that
all patients eligible and willing to participate in GCT are
identified. Our data suggest a lower uptake among young
Turkish/Moroccan breast cancer patients, mainly due to a
low referral rate among these groups. Further research is
needed with regard to the possible explanations for this low
referral rate.
Our study showed a relatively large group of young
Turkish and Moroccan breast cancer patients diagnosed
before the age of 40. Changes of lifestyle and reproduction
and the ageing of the migrant groups might eventually lead
to a growing proportion of cancer incidence among non-
Western minorities. Insight in the GCT referral and par-
ticipation rates among culturally diverse patient groups will
gain importance in order to plan future counseling practices
and to ensure equal access to cancer GCT.
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Appendix
See Fig. 1.
Reasons for not fulfilling inclusion criteria: 
* Turkish/Moroccan patients not included (n=87): 
BC diagnosed < 2007 or > 2012 n=54 (62%)
No breast cancer diagnosis n=11 (13%)
Other, e.g. diagnosed or treated in another hospital n=16 (18%)
Missing n=6 (7%)
† Comparative group patients not included (n=239): 
BC diagnosed < 2007 or > 2012 n=144 (60%)
No breast cancer diagnosis n=33 (14%)
Other, e.g. diagnosed or further treatment in another hospital n=46 (19%)
Missing n=16 (7%)
Turkish or Moroccan 
(n = 243)
Checklist filled in (n=156) Checklist filled in (n=321)
Not Turkish nor Moroccan 
(n = 10.788)
Not meeting inclusion criteria* 
(n = 87)
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